Scientist II/Senior Scientist I, LNP Process Development
Location: Brisbane
Posted on: June 23, 2025
|
|
Job Description:
OPPORTUNITY Mammoth Biosciences is seeking a highly motivated
Scientist II or Senior Scientist I to join our CMC team in a
hands-on, cross-functional role that blends scientific ingenuity
with operational excellence. This position is critical for
developing, optimizing, scaling, and characterizing LNP-based
delivery production processes for Mammoth's cutting-edge gene
editing platforms. The ideal candidate will thrive at the interface
of process development, analytics, and manufacturing—someone who
can transition smoothly between the bench and discussions with
external partners. This is a great opportunity to play a key role
in advancing transformative gene editing therapies into the clinic
and beyond. KEY RESPONSIBILITIES Design and optimize LNP
manufacturing processes by applying Quality by Design (QbD)
principles and execute Design of Experiments (DoEs) to identify and
control critical process parameters (CPPs) Optimize analytical
methods such as DLS, Ribogreen, HPLC-CAD, IP-RP-HPLC, and endotoxin
to identify and access critical quality attributes (CQAs) Interpret
analytical data to assess process robustness and guide iterative
development efforts Collaborate with internal teams to support
process improvements and drive innovation Clearly present
scientific findings and project updates in internal meetings and to
external collaborators Drive technology transfer activities with
external CDMO partners by preparing comprehensive technical
documentation such as development reports, process summaries, and
tech transfer packages to ensure successful external manufacturing
Stay current with emerging trends in LNP technologies and
contribute to strategic process improvements Track inventory, plan
experiments, and contribute to an organized, quality-focused lab
environment REQUIRED QUALIFICATIONS Ph.D. in Chemical Engineering,
Bioengineering, Pharmaceutical Sciences, Chemistry, or a related
field with minimum of 3 years relevant industry experience; or M.S.
with 6 years; or B.S. with 8 years Demonstrated expertise in LNP
formulation and process development, including hands-on experience
with microfluidic and high-shear mixing technologies, tangential
flow filtration and dead-end filtration Proficiency in analytical
characterization techniques for LNPs, including DLS,
fluorescence-based assays and HPLC/UPLC methods (CAD, UV, IP-RP,
SEC, IEX), including method development, troubleshooting, and data
interpretation Experience with in-process and drug product
stability studies Proven success in applying DoEs and statistical
analysis tools for process optimization Experience supporting
technology transfer of processes to external manufacturing
environments, with a strong understanding of tech transfer best
practices Demonstrated strong organizational skills A self-starter
with demonstrated strong troubleshooting skills, capable of driving
projects independently while contributing effectively in a
collaborative, multidisciplinary environment PREFERRED
QUALIFICATIONS Knowledge of regulatory expectations for CMC
development Familiarity with high-throughput screening methods
Exposure to cell-based assays for LNP functional characterization
Familiarity with data analysis tools and statistical methods such
as JMP Experience with AAV vector process development or a strong
interest and adaptability to learn viral delivery systems BENEFITS
Company-paid health/vision/dental benefits Unlimited vacation and
generous sick time Company-sponsored meals and snacks Wellness,
caregiver and ergonomics benefits 401(k) with company matching Base
Salary Range: $157,000 - $178,000 per year Actual base salary will
be determined by relevant professional experience, applicable
skills, and internal equity. Mammoth Biosciences is a biotechnology
company focused on leveraging its proprietary ultracompact CRISPR
systems to develop long-term curative therapies, as well as other
applications such as decentralized precision diagnostics. Founded
by CRISPR pioneer and Nobel laureate Jennifer Doudna and Trevor
Martin, Janice Chen, and Lucas Harrington, the company’s
ultracompact proteins are designed to enable in vivo gene editing
in difficult to reach tissues utilizing both nuclease applications
and new editing modalities beyond double stranded breaks, including
base editing, gene writing, and epigenetic editing. The company is
building out its pipeline of potential in vivo gene editing
therapeutics and capabilities and has partnerships with leading
pharmaceutical and biotechnology companies to broaden the reach of
its innovative and proprietary technology. Mammoth’s deep science
and industry experience, along with a robust and differentiated
intellectual property portfolio, have enabled the company to
further its mission to transform the lives of patients and deliver
on the full promise of CRISPR technologies. It is our policy and
intent to provide equal opportunity to all persons without regard
to race, color, religion, political affiliation, sex/gender
(including gender expression/identity, pregnancy, childbirth and
related medical conditions), marital status, registered domestic
partner status, sexual orientation, age, ancestry, national origin,
veteran status, disability, medical condition, genetic
characteristics, and/or any other basis protected by law. This
policy covers all facets of employment including, but not limited
to: recruitment, selection, placement, promotions, transfers,
demotions, terminations, training, and compensation. Mammoth
Biosciences requires that all employees be vaccinated against COVID
as a condition of at-will employment, with exceptions for medical
or religious reasons in compliance with local, state, and federal
law.
Keywords: , Gilroy , Scientist II/Senior Scientist I, LNP Process Development, Science, Research & Development , Brisbane, California